Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and ...

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I ...

We recently published a list of 13 AI News and Ratings You Probably Missed. In this article, we are going to take a look at ...

Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop new hardware and software optimized for the healthcare sector. The effort ...

Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial intelligence to develop new drug therapies. Absci hopes artificial ...

"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...

Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power ...

Absci Corporation has announced a strategic partnership with AMD to utilize AMD Instinct™ accelerators and ROCm™ software for advancing AI-driven drug discovery, specifically in de novo ...

The partnership will leverage AMD Instinct accelerators and ROCm software to support Absci’s advanced de novo antibody design models. The deal also includes a $20 million private investment in ...

AMD collaborates with Absci for AI drug discovery advancements. AMD makes a $20 million investment to boost drug research. The partnership will leverage AMD Instinct accelerators and ROCm software ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct ...